Stem Cell Therapy may aid in increasing endogenous collagen levels. Increased collagen leads to the preservation of the skin as it slows the aging process at a cellular level, thus allowing the skin to keep its youthful glow and bright appearance for a longer time.
Due to increase blood flow following stem cell therapy, more oxygenation is now reached to the vital organs which rises energy levels. Patients experience better performance during the day and greater sleep during the night, which is translated into an improvement in their sex lives, ease in pain, and overall better performance.
Cellular inflammation is the source of all pain. At a microscopical level pain starts with cellular swelling. Stem cell therapy reduces cellular inflammation by increasing the anti-inflammatory response leading to healing and repair. This ultimately improves the patient’s internal processes and enhance’s the body’s immune system and its healing mechanisms.
Stem Cell Therapy aims to restore integrity and functionality of the gastrointestinal tissue by stimulating the desired immune modulation, mainly by the expression of trophic factors and promoting a healthy microbiome environment.
By stimulating increased blood flow, Stem Cell Therapy can induce an environment for tissue oxygenation, nutrient distribution, healing, repair and, debris elimination.
Life expectancy has steadily increased around the world for over 200 years, and staying healthy has become an important goal to promote life quality.
Immunosenescence, referring to the aging immune system, refers to innate and adaptative immune changes that could have significant clinical consequences as the origin of many diseases such as infections, cancer, autoimmune disorders, and chronic inflammatory diseases. Several studies have concluded that an age-associated chronic proinflammatory state can contribute to degenerative diseases such as rheumatoid arthritis, atherosclerosis, and neurodegenerative diseases.
As we get older, we experience changes in the hematopoietic system, including a long-term reduction in the production and repopulation of immune cells[6,7], leading to an impaired immune defense against various infections and spontaneous inflammatory responses. These studies lead to the term “inflammaging”, referring to a persistent low-grade systemic pro-inflammatory status that appears in the normal aging process of mammals[10,11].
An important characteristic of inflammaging is an accumulation of damaged molecules and cellular debris because of its increased production and chronically inhibited repair functions in multiple tissues. Secretion of proinflammatory cytokines from senescent (aged) cells accumulated in tissues with age contributes to the onset of inflammaging. MSCs release an antiinflammatory microenvironment around them that influences the behavior of neighboring cells[14,15], such as endogenous stem cell recruitment, proliferation and change of cells; lower cell death, fibrosis and increasing blood flow[27-37]. MSC therapies target intrinsic repair enhancement and regenerative responses.
Due to the many properties of MSCs, they have been investigated as an anti-aging therapeutic [12,13]. MSC’s possess immuno-privileged properties, thereby they are considered safe for both autologous and allogeneic use[16-20]. Human MSC benefits from a single infusion can persist for months and multiple dosing can be well tolerated helping to sustained beneficial health effects[9,19,21-26].
Let us help you Recover your health back! Transform your life now with our Regenerative Therapies!
1. Franceschi C, Salvioli S, Garagnani P, de Eguileor M, Monti D, Capri M. Immunobiography and the heterogeneity of immune responses in the elderly: a focus on inflammaging and trained immunity. Immunol. 2017. 8:982.
2. Fulop T, Larbi A, Dupuis G, et al. Immunosenscence and inflammaging as two sides of the same coin: friends or foes? Front Immunol. 2018. 8:1960.
3. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016. 388:2023-38.
4. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002. 105:1135-43.
5. Heppner FL, Ransohoff RM, Becher B. Immne attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015. 16:358-72.
6. Yu KR, Espinoza DA, Wu C, et al. The impact of aging on primate hematopoiesis as interrogated by clonal tracking. Blood. 2018. 131:1195-205.
7. Pang WW, Price EA, Sahoo D, et al. Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age. Proc Natl Acad Sci USA. 2011. 107:20012-7.
8. Derhovanessian E, Maier AB, Beck R, et al. Hallmark features of immunosenescence are absent in familial lingevity. J Immunol. 2010. 185:4618-38.
9. Oliva AA, McClain-Moss L, Pena A, Drouillard A, Hare JM. Allogeneic mesenchymal stem cell therapy: a regenerative medicine approach to geroscience. Aging Med (Milton). 2019. 2(3):142-6.
10. Franceschi C, Bonafe M, Valensin S, et al. Inflammaging: an evolutionary perspective on immunosenescence. Ann NY Acad Sci. 2000. 908:244-54.
11. Le BC, Yu KR. Impact of mesenchymal stem cell senescence on inflammaging. BMB Rep. 2020. 53(2):65-73.
12. Franceschi C, Garagnani P, Vitale G, Capri M, Salvioli S. Inflammaging and ‘garb-aging’. Trends Endorcinol Metab. 2017. 28:199-212.
13. Robbins PD. Extracellular vesicles and aging. Stem Cell Investig. 2017- 4:98.
14. Yeo RW, Lai RC, Zhang B, et al. Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery. Adv Drug Deliv Rev. 2013. 65:336-41.
15. Mokarizadeh A, Delirezh N, Morshedi A, Mosayebi G, Farshid AA, Mardani K. Microvesicles derived from mesenchymal stem cells: potent organelles for induction of tolerogenic signaling. Immunol Lett. 2012. 147:47-54.
16. Glenn JD, Whartenby KA. Mesenchymal stem cells: emerging mechanisms of immunomodulation and therapy. World J Stem Cells. 2014. 6(5):526-39.
17. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008. 371(9624):1579-86.
18. Klyushnenkova E, Mosca JD, Zernetkina V, et al. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci. 2005. 12(1):47–57.
19. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE. 2012. 7(10):e47559.
20. Schuleri KH, Feigenbaum GS, Centola M, et al. Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cadiomiopathy. Eur Heart J. 2009. 30(22):2722-32.
21. Williams AR, Trachtenberg B, Velazquez DL, et al. Intramyocardial stem cells injection in patients with ischemic cardiomiopathy: functional recovery and reverse remodelling. Circ Res. 2011. 108(7):792-6.
22. Hatzistergos KE, Quevedo H, Oskouei BN, et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res. 2010. 107(7):913-22.
23. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012. 308(22).2369-79.
24. Quevedo HC, Hatzistergos KE, Oskouei BN, et al. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc Natl Acad Sci USA. 2009. 106(33): 13022-7.
25. von Bahr L, Batsis I, Moll G, et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engrafment and no ectopic tissue formation. Stem Cells. 2012. 30(7):1575-8.
26. Golpanian S, DiFede DL, Pujol MV, et al. Rationale and design of the allogeneic human mesenchymal stem cells (hMSC) in patients with aging frailty via intravenous delivery (CRATUS) study: a phase I/II, randomized, blinded and placebo controlled trial to evaluate the safety and potential efficacy of allogeneic human mesenchymal stem cell infusion in patients with aging frailty. Oncotarget. 2016. 7(11):11899-912.
27. Hubbard RE, O’Mahony MS, Savva GM, Calver BL, Woodhouse KW. Inflammation and frailty measures in older people. J Cell Mol Med. 2009. 13(9B):3103-9.
28. Collerton J, Martin-Ruiz C, Davies K, et al. Frailty and the role of inflammation, immunosenescence and cellular ageing in the very old: cross-sectional findings from the Newcastle 85+ study. Mech Ageing Dev. 2012. 133(6)456-66.
29. Schaap LA, Pluijm SM, Deeg DJ, et al. Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. J Gerontol A Biol Sci Med Sci. 2009. 64(11):1183-9.
30. Visser M, Pahor M, Taaffe DR, et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the health ABC study. J Gerontol A Biol Sci Med Sci. 2002. 57(5):M326-32.
31. Serviddio G, Romano AD, Greco A, et al. Frailty syndrome is associated with altered circulating redox balance and increased markers of oxidative stress. Int J Immunopathol Pharmacol. 2009. 22(3):819-27.
32. Tay L, Lim WS, Chan M, Ye RJ, Chong MS. The independent role of inflammation in physical frailty among older adults with mild cognitive impairment and mild-to-moderate Alzheimer’s disease. J Nutr Health Aging. 2016. 20(3):288-99.
33. Glenn JD, Whartenby KA. Mesenchymal stem cells: emerging mechanisms of immunomodulation and therapy. World J Stem Cells. 2014. 6(5):526-39.
34. Wang S, Qu X, Zhao RC. Clinical applications of mesenchymal stem cells. J Hematol Oncol. 2012. 5:19.
35. Yao X, Li H, Leng SX. Inflammation and immune system alterations in frailty. Clin Geriatr Med. 2011. 27(1):79-87.
36. Premer C, Blum A, Bellio MA, et al. Allogeneic mesenchymal stem cells restore endothelial function in heart failure by stimulating endothelial progenitor cells. EBioMedicine. 2015. 2(5):467-75.
37. Aso K, Tsuruhara A, Takagaki K, et al. Adipose-derived mesenchymal stem cells restore impaired mucosal immune responses in aged mice. PLoS ONE. 2016. 11(2): e0148185.